AHA Coding Clinic® for HCPCS - 2022 Quarter 2; Ask the Editor
Discontinued monoclonal antibody infusion
A patient with mild COVID-19 symptoms presented for an outpatient infusion of the monoclonal antibody treatment casirivimab and imdevimab. The infusion was initiated and after seven minutes with an infusion of 17mL of the medication, the patient chose to discontinue the treatment and left the facility declining post infusion observation. Is it appropriate to append a Modifier 52, Reduced Services , to HCPCS Level II code M0243 if the infusion was discontinued due to patient decision with no post-infusion monitoring? ...
Subscribe or sign in to view the full article.
Article Overview
This premium article discusses billing and reporting considerations for an outpatient monoclonal antibody infusion that was started but not completed after the patient chose to stop treatment. It is relevant to coding and billing professionals working with COVID-19 treatment services, HCPCS Level II reporting, and modifier usage, and it highlights that payer-specific policies may affect how the service is reported.
Why This Topic Matters
Interrupted infusion services can create uncertainty about how to report the encounter, especially when the patient declines to continue care or observation. The article helps readers understand the scope of the issue and the need to verify payer-specific guidance before submitting claims.
What You Will Learn
- How the article frames reporting issues for a discontinued outpatient infusion
- Why payer-specific policies matter for interrupted treatment services
- What general type of coding consideration is raised for reduced or incomplete services in this setting
- How the article connects COVID-19 infusion care with HCPCS Level II reporting
Who Should Read This
- Medical coders
- Coding auditors
- Billing staff
- Compliance professionals
- Revenue cycle professionals
Codes Discussed
Modifiers Discussed
Subscribe or sign in to view the full article.
Quick, Current, Complete - www.findacode.com